ArticleEClinicalMedicine2026

Measurable residual disease-guided combination of ibrutinib plus venetoclax versus FCR in previously untreated patients with intermediate-risk chronic lymphocytic leukaemia: a phase 2, randomised trial (ERADIC) from the FILO group.

Anne Quinquenel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.